Pharming Group (NASDAQ:PHAR – Get Rating) gapped up before the market opened on Monday . The stock had previously closed at $11.76, but opened at $12.52. Pharming Group shares last traded at $12.52, with a volume of 10 shares.

Wall Street Analyst Weigh In

Separately, TheStreet raised Pharming Group from a "d+" rating to a "c" rating in a research report on Monday, August 15th.

Pharming Group Stock Up 2.0 %

The company has a current ratio of 5.40, a quick ratio of 4.68 and a debt-to-equity ratio of 0.60. The firm has a market cap of $816 million, a price-to-earnings ratio of 30.49 and a beta of -0.30. The firm has a 50-day moving average of $10.63 and a two-hundred day moving average of $9.67.

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercialize protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema.

Featured Articles

• Get a free copy of the StockNews.com research report on Pharming Group (PHAR)
• Which Stocks Are Black Friday, Cyber Monday Winners & Losers?
• Three Reasons It's Time To Get Bullish On Organigram
• Opportunity Strikes! Hibbett, Inc Falls Flat On Strong Results
• Why Investors Are Eating Up Restaurant Brands International
• Zoom Video Continues to Work Through Normalization

Receive News & Ratings for Pharming Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharming Group and related companies with MarketBeat.com's FREE daily email newsletter.